**Supplementary Table 2. Summary of studies of pharmaceuticals used for the treatment of COVID-19**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | ***n*** | **Type of study** | **Severity** | **Study arms** | **Results** |
| Boulware *et al*.s1 | 821 | Randomized, double-blind, placebo-controlled trial | Exposure to a confirmed case within 4 days | HCQ-50%  Placebo-50% | HCQ did not prevent infection when used as a post-exposure prophylaxis |
| Skipper *et al*.s2 | 491 | Randomized, double-blind, placebo-controlled trial | Symptomatic non-hospitalized patient | HCQ-50%  Pacebo-50% | HCQ did not reduce symptom severity |
| Cao *et al*.s3 (LOTUS CHINA) | 199 | Randomized, open label, trial | All severity | LPV/r- 99  No LPV/r- 100 | Did not show any decrease in time to clinical improvement, mortality or viral load after addition of LPV/r |
| Beigel *et al*.s4  (ACTT1 study) | 1059 | Randomized, double-blind, placebo-controlled trial | Lower respiratory tract involvement | RDV-51%  Placebo-49% | RDV shortened the time to recovery |
| Wang *et al*.s5 | 237 | Randomized, double-blind placebo-controlled trial | Moderate/Severe | RDV-67%  Placebo-33% | RDV not associated with significant clinical improvement |
| Goldman *et al*.s6 | 397 | Randomized, open label trial | Moderate/Severe | RDV 5-day-50%  RDV 10-day-50% | For patients not requiring mechanical ventilation, 5-day treatment is enough. For patients requiring mechanical ventilation, 10-day may be required. |
| Spinner *et al*.s7 | 584 | Randomized, open label trial | Moderate | RDV 5-day-33%  RDV 10-day-33%  SOC-34% | No difference in clinical outcomes between 10 d vs. SOC. Statistically significant improvement in clinical outcomes in 5 d vs. SOC |
| The RECOVERY collaborative groups8 | 6425 | Randomized, open label trial | Hospitalized COVID patients | DEXA-33%  SOC-67% | Reduced mortality in those receiving oxygen therapy or mechanical ventilation |
| Ip *et al*.s9 | 547 | Retrospective observational cohort study | ICU patients | SOC-76%  TCZ-24% | TCZ showed a trend towards reduced mortality |
| Biran *et al*.s10 | 764 | Retrospective observational cohort study | ICU patients | SOC-73%  TCZ-27% | TCZ was associated with decreased mortality |
| Agarwal *et al*.s11 | 464 | Randomized, open label trial | Moderate | SOC-49%  CP-51% | CP not associated with reduction in progression or decreased mortality |

**References**

s1. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, *et al*. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020;383(6):517-525. doi: 10.1056/NEJMoa2016638.

s2. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, *et al*. Hydroxychloroquine in nonhospitalized adults with early COVID-19 : A randomized trial. Ann Intern Med 2020;173(8):623-631. doi: 10.7326/M20-4207.

s3. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, *et al*. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382(19):1787-1799. doi: 10.1056/NEJMoa2001282.

s4. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, *et al*. Remdesivir for the treatment of Covid-19 - Final report. N Engl J Med 2020;383(19):1813-1826. doi: 10.1056/NEJMoa2007764.

s5. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, *et al*. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9.

s6. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, *et al*. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020;383(19):1827-1837. doi: 10.1056/NEJMoa2015301.

s7. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, *et al*. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA 2020;324(11):1048-1057. doi: 10.1001/jama.2020.16349.

s8. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, *et al*. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384(8):693-704. doi: 10.1056/NEJMoa2021436.

s9. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, *et al*. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. PLoS One 2020;15(8):e0237693. doi: 10.1371/journal.pone.0237693.

s10. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, *et al*. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol 2020;2(10):e603-e612. doi: 10.1016/S2665-9913(20)30277-0.

s11. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:m3939. doi: 10.1136/bmj.m3939.